AIG07025 / AIGEN Sci - LARVOL DELTA

Discovery and preclinical characterization of AIG07025, a potent and selective USP1 inhibitor with broad combination potential (AACR 2026) - "Collectively, these data establish AIG07025 as a differentiated and highly selective USP1 inhibitor with broad combination potential and support its continued development for the treatment of BRCA/HRD-driven cancers. IND-enabling studies are currently ongoing."

Late-breaking abstract • Preclinical • Oncology • BRCA • HRD • USP1